Heat shock protein 70s as potential molecular targets for colon cancer therapeutics

Current Medicinal Chemistry

Volumn 23, Issue 28, 2016, Pages 3171-3188

  Black, Jennifer D ^a   Rezvani, Khosrow ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Apoptosis; Chemotherapy; Colorectal cancer; Heat shock protein; Mortalin 2; Targeted therapy

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; MORTALIN 2; ONCOPROTEIN; UBXN2A PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; UBIQUITIN; UBXN2A PROTEIN, HUMAN;

CANCER CELL; CANCER PATIENT; COLON CANCER; COLORECTAL CANCER; DRUG DESIGN; HUMAN; IN VIVO STUDY; MITOCHONDRIAL BIOGENESIS; MOLECULAR THERAPY; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLONIC NEOPLASMS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; ONCOGENE PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UBIQUITINS;

EID: 85011756185     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160627105033     Document Type: Review

References (208)

1. Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. CA Cancer J. Clin., 2014, 64(2), 104-117.
2. Haggar, F.A.; Boushey, R.P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg., 2009, 22(4), 191-197.
3. American Cancer Society. Colorectal cancer Facts and Figures, Atlanta: American Cancer Society, 2012.
4. Howlader, N.N.A.; Krapcho, M.; Garshell, J.; Miller, D.; Altekruse, S.F.; Kosary, C.L.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; Chen, H.S.; Feuer, E.J.; Cronin, K.A. SEER Cancer Statistics Review, 1975-2012; National Cancer Institute: Bethesda, MD, 2015.
5. Factsheets, S.C. SEER Cancer Statistics Factsheets: Colon and Rectum Cancer; National Cancer Institute: Bethesda, MD, 2015.
6. de Jong, M.C.; Pulitano, C.; Ribero, D.; Strub, J.; Mentha, G.; Schulick, R.D.; Choti, M.A.; Aldrighetti, L.; Capussotti, L.; Pawlik, T.M. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann. Surg., 2009, 250(3), 440-448.
7. Köhne, C.H. Successes and limitations of targeted cancer therapy in colon cancer. Prog. Tumor Res., 2014, 41, 36-50.
8. Hao, F.; Pysz, M.A.; Curry, K.J.; Haas, K.N.; Seedhouse, S.J.; Black, A.R.; Black, J.D. Protein kinase Cα signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium. J. Biol. Chem., 2011, 286(20), 18104-18117.
9. Pysz, M.A.; Hao, F.; Hizli, A.A.; Lum, M.A.; Swetzig, W.M.; Black, A.R.; Black, J.D. Differential regulation of cyclin D1 expression by protein kinase C α and ϵ signaling in intestinal epithelial cells. J. Biol. Chem., 2014, 289(32), 22268-22283.
10. Sane, S.; Abdullah, A.; Boudreau, D.A.; Autenried, R.K.; Gupta, B.K.; Wang, X.; Wang, H.; Schlenker, E.H.; Zhang, D.; Telleria, C.; Huang, L.; Chauhan, S.C.; Rezvani, K. Ubiquitin-like (UBX)-domain-containing protein, UBXN-2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. Cell Death Dis., 2014, 5, e1118.
11. Hwang, T.S.; Han, H.S.; Choi, H.K.; Lee, Y.J.; Kim, Y.J.; Han, M.Y.; Park, Y.M. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J. Gastroenterol. Hepatol., 2003, 18(6), 690-700.
12. Schmitt, E.; Maingret, L.; Puig, P.E.; Rerole, A.L.; Ghir-inghelli, F.; Hammann, A.; Solary, E.; Kroemer, G.; Garrido, C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res., 2006, 66(8), 4191-4197.
13. Sherman, M.Y.; Gabai, V.L. Hsp70 in cancer: back to the future. Oncogene, 2015, 34(32), 4153-4161.
14. Mosser, D.D.; Morimoto, R.I. Molecular chaperones and the stress of oncogenesis. Oncogene, 2004, 23(16), 2907-2918.
15. Mosser, D.D.; Caron, A.W.; Bourget, L.; Denis-Larose, C.; Massie, B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol. Cell. Biol., 1997, 17(9), 5317-5327.
16. Zhu, Q.; Xu, Y.M.; Wang, L.F.; Zhang, Y.; Wang, F.; Zhao, J.; Jia, L.T.; Zhang, W.G.; Yang, A.G. Heat shock protein 70 silencing enhances apoptosis inducing factor-mediated cell death in hepatocellular carcinoma HepG2 cells. Cancer Biol. Ther., 2009, 8(9), 792-798.
17. Rashmi, R.; Kumar, S.; Karunagaran, D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis, 2004, 25(2), 179-187.
18. Wadhwa, R.; Kaul, S.C.; Mitsui, Y.; Sugimoto, Y. Differential subcellular distribution of mortalin in mortal and immortal mouse and human fibroblasts. Exp. Cell Res., 1993, 207(2), 442-448.
19. Lu, W.J.; Lee, N.P.; Kaul, S.C.; Lan, F.; Poon, R.T.; Wadhwa, R.; Luk, J.M. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ., 2011, 18(6), 1046-1056.
20. Abdullah, A.; Sane, S.; Branick, K.A.; Freeling, J.L.; Wang, H.; Zhang, D.; Rezvani, K. A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2. Oncotarget, 2015, 6(27), 23561-23581.
21. Wu, P.K.; Hong, S.K.; Veeranki, S.; Karkhanis, M.; Starenki, D.; Plaza, J.A.; Park, J.I. A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/ MEK/extracellular signal-regulated kinase. Mol. Cell. Biol., 2013, 33(20), 4051-4067.
22. Yoo, J.Y.; Ryu, J.; Gao, R.; Yaguchi, T.; Kaul, S.C.; Wadhwa, R.; Yun, C.O. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-onco-lytic virus. J. Gene Med., 2010, 12(7), 586-595.
23. Wadhwa, R.; Takano, S.; Robert, M.; Yoshida, A.; Nomura, H.; Reddel, R.R.; Mitsui, Y.; Kaul, S.C. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. J. Biol. Chem., 1998, 273(45), 29586-29591.
24. Tai-Nagara, I.; Matsuoka, S.; Ariga, H.; Suda, T. Mortalin and DJ-1 coordinately regulate hematopoietic stem cell function through the control of oxidative stress. Blood, 2014, 123(1), 41-50.
25. Chen, J.; Liu, W.B.; Jia, W.D.; Xu, G.L.; Ma, J.L.; Huang, M.; Deng, Y.R.; Li, J.S. Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int. J. Oncol., 2014, 44(1), 247-255.
26. Dundas, S.R.; Lawrie, L.C.; Rooney, P.H.; Murray, G.I. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J. Pathol., 2005, 205(1), 74-81.
27. Oki, E.; Saeki, K. A. H.; Ohga, T.; Kakeji, Y.; Tsujitani, S.; Kusumoto, T.; Maehara, Y. Maehara, Prognostic significance of mortalin expresion in gastric adenocarcinoma with wild-type p53. J. Clin. Oncol., 2011, 29 abstr e14662
28. Rozenberg, P.; Kocsis, J.; Saar, M.; Prohászka, Z.; Füst, G.; Fishelson, Z. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer. Int. J. Cancer, 2013, 133(2), 514-518.
29. Hagan, S.; Orr, M.C.; Doyle, B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J., 2013, 4(1), 3.
30. Lombardi, L.; Morelli, F.; Cinieri, S.; Santini, D.; Silvestris, N.; Fazio, N.; Orlando, L.; Tonini, G.; Colucci, G.; Maiello, E. Adjuvant colon cancer chemotherapy: where we are and where we’ll go. Cancer Treat. Rev., 2010, 36(Suppl. 3), S34-S41.
31. He, J.; Efron, J.E. Screening for colorectal cancer. Adv. Surg., 2011, 45, 31-44.
32. Gustavsson, B.; Carlsson, G.; Machover, D.; Petrelli, N.; Roth, A.; Schmoll, H.J.; Tveit, K.M.; Gibson, F. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin. Colorectal Cancer, 2015, 14(1), 1-10.
33. Demartino, G.N.; Gillette, T.G. Proteasomes: machines for all reasons. Cell, 2007, 129(4), 659-662.
34. Gill, S.; Blackstock, A.W.; Goldberg, R.M. Colorectal cancer. Mayo Clin. Proc., 2007, 82(1), 114-129.
35. Ciombor, K.K.; Wu, C.; Goldberg, R.M. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med., 2015, 66, 83-95.
36. Heidelberger, C.; Chaudhuri, N.K.; Danneberg, P.; Mooren, D.; Griesbach, L.; Duschinsky, R.; Schnitzer, R.J.; Pleven, E.; Scheiner, J. Fluorinated pyrimidines, a new class of tu- mour-inhibitory compounds. Nature, 1957, 179(4561), 663-666.
37. Danenberg, P.V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 1977, 473(2), 73-92.
38. Ullman, B.; Lee, M.; Martin, D.W., Jr; Santi, D.V. Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc. Natl. Acad. Sci. USA, 1978, 75(2), 980-983.
39. Mini, E.; Trave, F.; Rustum, Y.M.; Bertino, J.R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol. Ther., 1990, 47(1), 1-19.
40. Poon, M.A.; O’Connell, M.J.; Moertel, C.G.; Wieand, H.S.; Cullinan, S.A.; Everson, L.K.; Krook, J.E.; Mailliard, J.A.; Laurie, J.A.; Tschetter, L.K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 1989, 7(10), 1407-1418.
41. Poon, M.A.; O’Connell, M.J.; Wieand, H.S.; Krook, J.E.; Gerstner, J.B.; Tschetter, L.K.; Levitt, R.; Kardinal, C.G.; Mailliard, J.A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 1991, 9(11), 1967-1972.
42. Thirion, P.; Michiels, S.; Pignon, J.P.; Buyse, M.; Braud, A.C.; Carlson, R.W.; O’Connell, M.; Sargent, P.; Piedbois, P. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol., 2004, 22(18), 3766-3775.
43. Kunimoto, T.; Nitta, K.; Tanaka, T.; Uehara, N.; Baba, H.; Takeuchi, M.; Yokokura, T.; Sawada, S.; Miyasaka, T.; Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperi-dino)-1-piperidino]carbonyloxy-camptothec in, a novel wa-ter-soluble derivative of camptothecin, against murine tumors. Cancer Res., 1987, 47(22), 5944-5947.
44. Kidani, Y.; Noji, M.; Tashiro, T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gan, 1980, 71(5), 637-643.
45. Saltz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbacher, L.; Moore, M.J.; Maroun, J.A.; Ackland, S.P.; Locker, P.K.; Pirotta, N.; Elfring, G.L.; Miller, L.L. Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2000, 343(13), 905-914.
46. Cassidy, J.; Tabernero, J.; Twelves, C.; Brunet, R.; Butts, C.; Conroy, T.; Debraud, F.; Figer, A.; Grossmann, J.; Sawada, N.; Schöffski, P.; Sobrero, A.; Van Cutsem, E.; Díaz-Rubio, E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(11), 2084-2091.
47. Fakih, M.G. Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol., 2015, 33(16), 1809-1824.
48. Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer, 2011, 2(12), 1097-1105.
49. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
50. Guan, Z.Z.; Xu, J.M.; Luo, R.C.; Feng, F.Y.; Wang, L.W.; Shen, L.; Yu, S.Y.; Ba, Y.; Liang, J.; Wang, D.; Qin, S.K.; Wang, J.J.; He, J.; Qi, C.; Xu, R.H. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ART-IST trial. Chin J Cancer, 2011, 30(10), 682-689.
51. Samelis, G.F.; Ekmektzoglou, K.A.; Tsiakou, A.; Konsta-doulakis, M. The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit. Hepatogastroenterology, 2011, 58(112), 1968-1971.
52. Kirstein, M.M.; Lange, A.; Prenzler, A.; Manns, M.P.; Ku-bicka, S.; Vogel, A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist, 2014, 19(11), 1156-1168.
53. Wilhelm, S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schütz, G.; Thierauch, K.H.; Zopf, D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer, 2011, 129(1), 245-255.
54. Davies, R.L.; Grosse, V.A.; Kucherlapati, R.; Bothwell, M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc. Natl. Acad. Sci. USA, 1980, 77(7), 4188-4192.
55. Van Cutsem, E.; Köhne, C.H.; Hitre, E.; Zaluski, J.; Chang Chien, C.R.; Makhson, A.; D’Haens, G.; Pintér, T.; Lim, R.; Bodoky, G.; Roh, J.K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 2009, 360(14), 1408-1417.
56. Douillard, J.Y.; Siena, S.; Cassidy, J.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Oliner, K.S.; Wolf, M.; Gansert, J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol., 2010, 28(31), 4697-4705.
57. Price, T.J.; Peeters, M.; Kim, T.W.; Li, J.; Cascinu, S.; Ruff, P.; Suresh, A.S.; Thomas, A.; Tjulandin, S.; Zhang, K.; Murugappan, S.; Sidhu, R. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (AS-PECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol., 2014, 15(6), 569-579.
58. Fisher, G.A.; Kuo, T.; Ramsey, M.; Schwartz, E.; Rouse, R.V.; Cho, C.D.; Halsey, J.; Sikic, B.I. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin. Cancer Res., 2008, 14(21), 7074-7079.
59. Meyerhardt, J.A.; Zhu, A.X.; Enzinger, P.C.; Ryan, D.P.; Clark, J.W.; Kulke, M.H.; Earle, C.C.; Vincitore, M.; Mich-elini, A.; Sheehan, S.; Fuchs, C.S. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J. Clin. Oncol., 2006, 24(12), 1892-1897.
60. Rothenberg, M.L.; LaFleur, B.; Levy, D.E.; Washington, M.K.; Morgan-Meadows, S.L.; Ramanathan, R.K.; Berlin, J.D.; Benson, A.B., III; Coffey, R.J. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol., 2005, 23(36), 9265-9274.
61. Townsley, C.A.; Major, P.; Siu, L.L.; Dancey, J.; Chen, E.; Pond, G.R.; Nicklee, T.; Ho, J.; Hedley, D.; Tsao, M.; Moore, M.J.; Oza, A.M. Phase II study of erlotinib (OSI- 774) in patients with metastatic colorectal cancer. Br. J. Cancer, 2006, 94(8), 1136-1143.
62. Lièvre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Côté, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res., 2006, 66(8), 3992-3995.
63. Douillard, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; Rivera, F.; Kocákova, I.; Ruff, P.; Błasińska-Morawiec, M.; Šmakal, M.; Canon, J.L.; Rother, M.; Williams, R.; Rong, A.; Wiezorek, J.; Sidhu, R.; Patterson, S.D. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med., 2013, 369(11), 1023-1034.
64. Sridharan, M.; Hubbard, J.M.; Grothey, A. Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions. http://www.cancernet-work.com/on-cology-journal/colorectal-cancer-how-emerg-ing-molecu-lar-understanding-affects-treatment-decisions# sthash.VoA-8VAvv.dpuf
65. De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; Penault-Llorca, F.; Rougier, P.; Vincenzi, B.; Santini, D.; Tonini, G.; Cap-puzzo, F.; Frattini, M.; Molinari, F.; Saletti, P.; De Dosso, S.; Martini, M.; Bardelli, A.; Siena, S.; Sartore-Bianchi, A.; Tabernero, J.; Macarulla, T.; Di Fiore, F.; Gangloff, A.O.; Ciardiello, F.; Pfeiffer, P.; Qvortrup, C.; Hansen, T.P.; Van Cutsem, E.; Piessevaux, H.; Lambrechts, D.; Delorenzi, M.; Tejpar, S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol., 2010, 11(8), 753-762.
66. Di Nicolantonio, F.; Martini, M.; Molinari, F.; Sartore-Bianchi, A.; Arena, S.; Saletti, P.; De Dosso, S.; Mazzuc-chelli, L.; Frattini, M.; Siena, S.; Bardelli, A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol., 2008, 26(35), 5705-5712.
67. Laurent-Puig, P.; Cayre, A.; Manceau, G.; Buc, E.; Bachet, J.B.; Lecomte, T.; Rougier, P.; Lievre, A.; Landi, B.; Boige, V.; Ducreux, M.; Ychou, M.; Bibeau, F.; Bouché, O.; Reid, J.; Stone, S.; Penault-Llorca, F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol., 2009, 27(35), 5924-5930.
68. Souglakos, J.; Philips, J.; Wang, R.; Marwah, S.; Silver, M.; Tzardi, M.; Silver, J.; Ogino, S.; Hooshmand, S.; Kwak, E.; Freed, E.; Meyerhardt, J.A.; Saridaki, Z.; Georgoulias, V.; Finkelstein, D.; Fuchs, C.S.; Kulke, M.H.; Shivdasani, R.A. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer, 2009, 101(3), 465-472.
69. Stintzing, S.; Kapaun, C.; Laubender, R.P.; Jung, A.; Neu-mann, J.; Modest, D.P.; Giessen, C.; Moosmann, N.; Wol-lenberg, A.; Kirchner, T.; Heinemann, V. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int. J. Cancer, 2013, 132(1), 236-245.
70. Lipson, E.J.; Sharfman, W.H.; Drake, C.G.; Wollner, I.; Taube, J.M.; Anders, R.A.; Xu, H.; Yao, S.; Pons, A.; Chen, L.; Pardoll, D.M.; Brahmer, J.R.; Topalian, S.L. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res., 2013, 19(2), 462-468.
71. Swaika, A.; Hammond, W.A.; Joseph, R.W. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol. Immunol., 2015, 67(2 Pt A), 4-17.
72. Langleben, A.; Supko, J. G.; Hotte, S. J.; Batist, G.; Hirte, H. W.; Rogoff, H.; Li, Y.; Li, W.; Kerstein, D.; Leggett, D.; Hitron, M. J.; Li, C. A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. J. Clin. Oncol., 2013, 31 abstr 2542
73. Corcoran, R.B.; Ebi, H.; Turke, A.B.; Coffee, E.M.; Ni-shino, M.; Cogdill, A.P.; Brown, R.D.; Della Pelle, P.; Dias-Santagata, D.; Hung, K.E.; Flaherty, K.T.; Piris, A.; Wargo, J.A.; Settleman, J.; Mino-Kenudson, M.; Engelman, J.A. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov., 2012, 2(3), 227-235.
74. Prahallad, A.; Sun, C.; Huang, S.; Di Nicolantonio, F.; Salazar, R.; Zecchin, D.; Beijersbergen, R.L.; Bardelli, A.; Bernards, R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387), 100-103.
75. Hong, D.S.; Morris, V.K.; Fu, S.; Overman, M.J.; Piha-Paul, S.A.; Kee, B.K. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J. Clin. Oncol., 2014, 32(suppl 5s) abstr 3516
76. Corcoran, R. B.; Atreya, C. E.; Falchook, G. S.; Infante, J. R.; Hamid, O.; Messersmith, W. A.; Daud, A.; Kwak, E. L.; Ryan, D.; Kurzrock, R.; Sun, P.; Cunningham, E. A.; Or-ford, K. W.; Motwani, M.; Bai, Y.; Patel, K.; Venook, A. P.; Kopetz, S. Phase 1-2 trial of the BRAF inhibitor dabraf-enib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J. Clin. Oncol., 2014, 32(suppl 5s) abstr 3517
77. Misale, S.; Arena, S.; Lamba, S.; Siravegna, G.; Lallo, A.; Hobor, S.; Russo, M.; Buscarino, M.; Lazzari, L.; Sartore-Bianchi, A.; Bencardino, K.; Amatu, A.; Lauricella, C.; Valtorta, E.; Siena, S.; Di Nicolantonio, F.; Bardelli, A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med., 2014, 6(224), 224ra26.
78. Ritossa, F. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia, 1962, 18(12), 571-573.
79. Ritossa, F. Discovery of the heat shock response. Cell Stress Chaperones, 1996, 1(2), 97-98.
80. Morimoto, R.I.; Kline, M.P.; Bimston, D.N.; Cotto, J.J. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem., 1997, 32, 17-29.
81. Jolly, C.; Morimoto, R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst., 2000, 92(19), 1564-1572.
82. Richter, K.; Haslbeck, M.; Buchner, J. The heat shock response: life on the verge of death. Mol. Cell, 2010, 40(2), 253-266.
83. Morimoto, R.I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev., 1998, 12(24), 3788-3796.
84. Liu, Y.; Chang, A. Heat shock response relieves ER stress. EMBO J., 2008, 27(7), 1049-1059.
85. Marcu, M.G.; Doyle, M.; Bertolotti, A.; Ron, D.; Hender-shot, L.; Neckers, L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol. Cell. Biol., 2002, 22(24), 8506-8513.
86. Hao, R.; Nanduri, P.; Rao, Y.; Panichelli, R.S.; Ito, A.; Yoshida, M.; Yao, T.P. Proteasomes activate aggresome disassembly and clearance by producing unanchored ubiquitin chains. Mol. Cell, 2013, 51(6), 819-828.
87. Nanduri, P.; Hao, R.; Fitzpatrick, T.; Yao, T.P. Chaperone-mediated 26S proteasome remodeling facilitates free K63 ubiquitin chain production and aggresome clearance. J. Biol. Chem., 2015, 290(15), 9455-9464.
88. Ryhänen, T.; Hyttinen, J.M.; Kopitz, J.; Rilla, K.; Kuusisto, E.; Mannermaa, E.; Viiri, J.; Holmberg, C.I.; Immonen, I.; Meri, S.; Parkkinen, J.; Eskelinen, E.L.; Uusitalo, H.; Salminen, A.; Kaarniranta, K. Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in auto-phagy-mediated proteolysis in human retinal pigment epithelial cells. J. Cell. Mol. Med., 2009, 13(9B), 3616-3631.
89. Liang, P.; MacRae, T.H. Molecular chaperones and the cytoskeleton. J. Cell Sci., 1997, 110(Pt 13), 1431-1440.
90. Welch, W.J.; Suhan, J.P. Morphological study of the mammalian stress response: characterization of changes in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat fibroblasts after heat-shock treatment. J. Cell Biol., 1985, 101(4), 1198-1211.
91. Masuda, Y.; Shima, G.; Aiuchi, T.; Horie, M.; Hori, K.; Nakajo, S.; Kajimoto, S.; Shibayama-Imazu, T.; Nakaya, K. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxy-isovalerylshikonin. J. Biol. Chem., 2004, 279(41), 42503-42515.
92. Nylandsted, J.; Gyrd-Hansen, M.; Danielewicz, A.; Fehrenbacher, N.; Lademann, U.; Høyer-Hansen, M.; Weber, E.; Multhoff, G.; Rohde, M.; Jäättelä, M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med., 2004, 200(4), 425-435.
93. Horváth, I.; Multhoff, G.; Sonnleitner, A.; Vígh, L. Mem-brane-associated stress proteins: more than simply chaperones. Biochim. Biophys. Acta, 2008, 1778(7-8), 1653-1664.
94. Takayama, S.; Reed, J.C.; Homma, S. Heat-shock proteins as regulators of apoptosis. Oncogene, 2003, 22(56), 9041-9047.
95. Balch, W.E.; Morimoto, R.I.; Dillin, A.; Kelly, J.W. Adapting proteostasis for disease intervention. Science, 2008, 319(5865), 916-919.
96. Romanucci, M.; Bastow, T.; Della Salda, L. Heat shock proteins in animal neoplasms and human tumours--a comparison. Cell Stress Chaperones, 2008, 13(3), 253-262.
97. Manié, S.N.; Lebeau, J.; Chevet, E. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 3. Orchestrating the unfolded protein response in oncogenesis: an update. Am. J. Physiol. Cell Physiol., 2014, 307(10), C901-C907.
98. Chevet, E.; Hetz, C.; Samali, A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov., 2015, 5(6), 586-597.
99. Creagh, E.M.; Sheehan, D.; Cotter, T.G. Heat shock pro-teins--modulators of apoptosis in tumour cells. Leukemia, 2000, 14(7), 1161-1173.
100. Nylandsted, J.; Rohde, M.; Brand, K.; Bastholm, L.; Elling, F.; Jäättelä, M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci. USA, 2000, 97(14), 7871-7876.
101. Didelot, C.; Schmitt, E.; Brunet, M.; Maingret, L.; Parcellier, A.; Garrido, C. Heat shock proteins: endogenous modulators of apoptotic cell death. Handb. Exp. Pharmacol, 2006, 172, 171-98.
102. Jego, G.; Hazoumé, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett., 2013, 332(2), 275-285.
103. Calderwood, S.K.; Sherman, M.Y.; Ciocca, D.R. Heat Shock Proteins in Cancer, 1 ed.; Springer: Netherlands, 2007.
104. Milićević, Z.T.; Petković, M.Z.; Drndarević, N.C.; Pavlović, M.D.; Todorović, V.N. Expression of heat shock protein 70 (HSP70) in patients with colorectal adenocarci-noma--immunohistochemistry and Western blot analysis. Neoplasma, 2007, 54(1), 37-45.
105. Grivicich, I.; Regner, A.; Zanoni, C.; Correa, L.P.; Jotz, G.P.; Henriques, J.A.; Schwartsmann, G.; da Rocha, A.B. Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines. Int. J. Colorectal Dis., 2007, 22(10), 1201-1208.
106. Gurbuxani, S.; Bruey, J.M.; Fromentin, A.; Larmonier, N.; Parcellier, A.; Jäättelä, M.; Martin, F.; Solary, E.; Garrido, C. Selective depletion of inducible HSP70 enhances immu-nogenicity of rat colon cancer cells. Oncogene, 2001, 20(51), 7478-7485.
107. Juhasz, K.; Lipp, A.M.; Nimmervoll, B.; Sonnleitner, A.; Hesse, J.; Haselgruebler, T.; Balogi, Z. The complex function of hsp70 in metastatic cancer. Cancers (Basel), 2013, 6(1), 42-66.
108. Campanella, C.; Rappa, F.; Sciumè, C.; Marino Gammazza, A.; Barone, R.; Bucchieri, F.; David, S.; Curcurù, G.; Caruso Bavisotto, C.; Pitruzzella, A.; Geraci, G.; Modica, G.; Farina, F.; Zummo, G.; Fais, S.; Conway de Macario, E.; Macario, A.J.; Cappello, F. Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. Cancer, 2015, 121(18), 3230-3239.
109. Bauer, K.; Nitsche, U.; Slotta-Huspenina, J.; Drecoll, E.; von Weyhern, C.H.; Rosenberg, R.; Höfler, H.; Langer, R. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. Cell Oncol. (Dordr.), 2012, 35(3), 197-205.
110. Khalil, A.A.; Kabapy, N.F.; Deraz, S.F.; Smith, C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta, 2011, 1816(2), 89-104.
111. Hamelin, C.; Cornut, E.; Poirier, F.; Pons, S.; Beaulieu, C.; Charrier, J.P.; Haïdous, H.; Cotte, E.; Lambert, C.; Piard, F.; Ataman-Önal, Y.; Choquet-Kastylevsky, G. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J., 2011, 278(24), 4845-4859.
112. O’Dwyer, D.; Ralton, L.D.; O’Shea, A.; Murray, G.I. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One, 2011, 6(11), e27718.
113. Melle, C.; Bogumil, R.; Ernst, G.; Schimmel, B.; Bleul, A.; von Eggeling, F. Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics, 2006, 6(8), 2600-2608.
114. Hadchity, E.; Aloy, M.T.; Paulin, C.; Armandy, E.; Watkin, E.; Rousson, R.; Gleave, M.; Chapet, O.; Rodriguez-Lafrasse, C. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol. Ther., 2009, 17(8), 1387-1394.
115. Guttmann, D.M.; Koumenis, C. The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer Biol. Ther., 2011, 12(12), 1023-1031.
116. Ciocca, D.R.; Clark, G.M.; Tandon, A.K.; Fuqua, S.A.; Welch, W.J.; McGuire, W.L. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J. Natl. Cancer Inst., 1993, 85(7), 570-574.
117. Oskay Halacli, S.; Halacli, B.; Altundag, K. The significance of heat shock proteins in breast cancer therapy. Med. Oncol., 2013, 30(2), 575.
118. Rohde, M.; Daugaard, M.; Jensen, M.H.; Helin, K.; Nylandsted, J.; Jäättelä, M. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev., 2005, 19(5), 570-582.
119. Matera, L.; Forno, S.; Galetto, A.; Moro, F.; Garetto, S.; Mussa, A. Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway. Cell. Mol. Biol. Lett., 2007, 12(2), 268-279.
120. Tweedle, E.M.; Khattak, I.; Ang, C.W.; Nedjadi, T.; Jenkins, R.; Park, B.K.; Kalirai, H.; Dodson, A.; Azadeh, B.; Terlizzo, M.; Grabsch, H.; Mueller, W.; Myint, S.; Clark, P.; Wong, H.; Greenhalf, W.; Neoptolemos, J.P.; Rooney, P.S.; Costello, E. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut, 2010, 59(11), 1501-1510.
121. Sebastiani, V.; Botti, C.; Di Tondo, U.; Visca, P.; Pizzuti, L.; Santeusanio, G.; Alo, P.L. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res., 2006, 26(4B), 2983-2987.
122. Mori, D.; Nakafusa, Y.; Miyazaki, K.; Tokunaga, O. Differential expression of Janus kinase 3 (JAK3), matrix metal-loproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. Pathol. Res. Pract., 2005, 201(12), 777-789.
123. Cappello, F.; Bellafiore, M.; Palma, A.; David, S.; Marcianò, V.; Bartolotta, T.; Sciumè, C.; Modica, G.; Farina, F.; Zummo, G.; Bucchieri, F. 60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur. J. Histochem., 2003, 47(2), 105-110.
124. Cappello, F.; David, S.; Rappa, F.; Bucchieri, F.; Marasà, L.; Bartolotta, T.E.; Farina, F.; Zummo, G. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer, 2005, 5, 139.
125. He, Y.; Wu, Y.; Mou, Z.; Li, W.; Zou, L.; Fu, T.; Zhang, A.; Xiang, D.; Xiao, H.; Wang, X. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin. Appl., 2007, 1(3), 336-342.
126. Murphy, M.E. The HSP70 family and cancer. Carcinogenesis, 2013, 34(6), 1181-1188.
127. Drecoll, E.; Nitsche, U.; Bauer, K.; Berezowska, S.; Slotta-Huspenina, J.; Rosenberg, R.; Langer, R. Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. Int. J. Colorectal Dis., 2014, 29(6), 663-671.
128. Saturno, G.; Valenti, M.; De Haven Brandon, A.; Thomas, G.V.; Eccles, S.; Clarke, P.A.; Workman, P. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget, 2013, 4(8), 1185-1198.
129. Moser, C.; Lang, S.A.; Kainz, S.; Gaumann, A.; Fichtner-Feigl, S.; Koehl, G.E.; Schlitt, H.J.; Geissler, E.K.; Stoeltz-ing, O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol. Cancer Ther., 2007, 6(11), 2868-2878.
130. Chen, W-S.; Lee, C-C.; Hsu, Y-M.; Chen, C-C.; Huang, T-S. Identification of heat shock protein 90α as an IMH-2 epi-tope-associated protein and correlation of its mRNA over- expression with colorectal cancer metastasis and poor prognosis. Int. J. Colorectal Dis., 2011, 26(8), 1009-1017.
131. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5(10), 761-772.
132. Vasilevskaya, I.A.; Rakitina, T.V.; O’Dwyer, P.J. Gel-danamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res., 2003, 63(12), 3241-3246.
133. Clarke, P.A.; Hostein, I.; Banerji, U.; Stefano, F.D.; Ma-loney, A.; Walton, M.; Judson, I.; Workman, P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, 2000, 19(36), 4125-4133.
134. Melnyk, A.; Rieger, H.; Zimmermann, R. Co-chaperones of the mammalian endoplasmic reticulum. Subcell. Biochem., 2015, 78, 179-200.
135. Kuo, L.J.; Hung, C.S.; Chen, W.Y.; Chang, Y.J.; Wei, P.L. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth. J. Surg. Res., 2013, 185(1), 264-272.
136. Hardy, B.; Raiter, A.; Yakimov, M.; Vilkin, A.; Niv, Y. Colon cancer cells expressing cell surface GRP78 as a marker for reduced tumorigenicity. Cell Oncol. (Dordr.), 2012, 35(5), 345-354.
137. Chang, Y.J.; Chen, W.Y.; Huang, C.Y.; Liu, H.H.; Wei, P.L. Glucose-regulated protein 78 (GRP78) regulates colon cancer metastasis through EMT biomarkers and the NRF-2/HO-1 pathway. Tumour Biol., 2015, 36(3), 1859-1869.
138. Vaiopoulos, A.G.; Kostakis, I.D.; Koutsilieris, M.; Pa-pavassiliou, A.G. Colorectal cancer stem cells. Stem Cells, 2012, 30(3), 363-371.
139. Huang, E.H.; Wicha, M.S. Colon cancer stem cells: implications for prevention and therapy. Trends Mol. Med., 2008, 14(11), 503-509.
140. Morita, R.; Nishizawa, S.; Torigoe, T.; Takahashi, A.; Ta-mura, Y.; Tsukahara, T.; Kanaseki, T.; Sokolovskaya, A.; Kochin, V.; Kondo, T.; Hashino, S.; Asaka, M.; Hara, I.; Hirohashi, Y.; Sato, N. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci., 2014, 105(4), 389-395.
141. Wadhwa, R.; Kaul, S.C.; Sugimoto, Y.; Mitsui, Y. Induction of cellular senescence by transfection of cytosolic mortalin cDNA in NIH 3T3 cells. J. Biol. Chem., 1993, 268(30), 22239-22242.
142. Kaul, S.C.; Deocaris, C.C.; Wadhwa, R. Three faces of mortalin: a housekeeper, guardian and killer. Exp. Gerontol., 2007, 42(4), 263-274.
143. Sadekova, S.; Lehnert, S.; Chow, T.Y. Induction of PBP74/mortalin/Grp75, a member of the hsp70 family, by low doses of ionizing radiation: a possible role in induced radioresistance. Int. J. Radiat. Biol., 1997, 72(6), 653-660.
144. Mayer, M.P.; Bukau, B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci., 2005, 62(6), 670-684.
145. Rassow, J.; Maarse, A.C.; Krainer, E.; Kübrich, M.; Müller, H.; Meijer, M.; Craig, E.A.; Pfanner, N. Mitochondrial protein import: biochemical and genetic evidence for interaction of matrix hsp70 and the inner membrane protein MIM44. J. Cell Biol., 1994, 127(6 Pt 1), 1547-1556.
146. Neupert, W.; Brunner, M. The protein import motor of mitochondria. Nat. Rev. Mol. Cell Biol., 2002, 3(8), 555-565.
147. Craig, E.A.; Kramer, J.; Shilling, J.; Werner-Washburne, M.; Holmes, S.; Kosic-Smithers, J.; Nicolet, C.M. SSC1, an essential member of the yeast HSP70 multigene family, en- codes a mitochondrial protein. Mol. Cell. Biol., 1989, 9(7), 3000-3008.
148. Kimura, K.; Tanaka, N.; Nakamura, N.; Takano, S.; Oh-kuma, S. Knockdown of mitochondrial heat shock protein 70 promotes progeria-like phenotypes in caenorhabditis elegans. J. Biol. Chem., 2007, 282(8), 5910-5918.
149. Gestl, E.E.; Anne Böttger, S. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines. Biochem. Biophys. Res. Commun., 2012, 423(2), 411-416.
150. Deocaris, C.C.; Lu, W.J.; Kaul, S.C.; Wadhwa, R. Drugga-bility of mortalin for cancer and neuro-degenerative disorders. Curr. Pharm. Des., 2013, 19(3), 418-429.
151. Starenki, D.; Hong, S.K.; Lloyd, R.V.; Park, J.I. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. Oncogene, 2015, 34(35), 4624-4634.
152. Karkhanis, M.; Park, J.I. Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells. Cell. Signal., 2015, 27(3), 479-486.
153. Sun, P.; Yoshizuka, N.; New, L.; Moser, B.A.; Li, Y.; Liao, R.; Xie, C.; Chen, J.; Deng, Q.; Yamout, M.; Dong, M.Q.; Frangou, C.G.; Yates, J.R., III; Wright, P.E.; Han, J. PRAK is essential for ras-induced senescence and tumor suppression. Cell, 2007, 128(2), 295-308.
154. Yang, L.; Guo, W.; Zhang, Q.; Li, H.; Liu, X.; Yang, Y.; Zuo, J.; Liu, W. Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. J. Mol. Biol., 2011, 414(5), 654-666.
155. Guo, W.; Yan, L.; Yang, L.; Liu, X.; e, Q.; Gao, P.; Ye, X.; Liu, W.; Zuo, J. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma. PLoS One, 2014, 9(1), e85766.
156. Saar Ray, M.; Moskovich, O.; Iosefson, O.; Fishelson, Z. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity. J. Biol. Chem., 2014, 289(21), 15014-15022.
157. Ryu, J.; Kaul, Z.; Yoon, A.R.; Liu, Y.; Yaguchi, T.; Na, Y.; Ahn, H.M.; Gao, R.; Choi, I.K.; Yun, C.O.; Kaul, S.C.; Wadhwa, R. Identification and functional characterization of nuclear mortalin in human carcinogenesis. J. Biol. Chem., 2014, 289(36), 24832-24844.
158. Lu, W.J.; Lee, N.P.; Kaul, S.C.; Lan, F.; Poon, R.T.; Wadhwa, R.; Luk, J.M. Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int. J. Cancer, 2011, 129(8), 1806-1814.
159. Feng, Y.; Ariza, M.E.; Goulet, A.C.; Shi, J.; Nelson, M.A. Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria. Biochem. J., 2005, 392(Pt 1), 65-73.
160. Londono, C.; Osorio, C.; Gama, V.; Alzate, O. Mortalin, apoptosis, and neurodegeneration. Biomolecules, 2012, 2(1), 143-164.
161. Ko, J.H.; Gu, W.; Lim, I.; Zhou, T.; Bang, H. Expression profiling of mitochondrial voltage-dependent anion chan-nel-1 associated genes predicts recurrence-free survival in human carcinomas. PLoS One, 2014, 9(10), e110094.
162. Schwarzer, C.; Barnikol-Watanabe, S.; Thinnes, F.P.; Hilschmann, N. Voltage-dependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74. Int. J. Biochem. Cell Biol., 2002, 34(9), 1059-1070.
163. Bhat, S.S.; Anand, D.; Khanday, F.A. p66Shc as a switch in bringing about contrasting responses in cell growth: impli- cations on cell proliferation and apoptosis. Mol. Cancer, 2015, 14, 76.
164. Grossman, S.R.; Lyle, S.; Resnick, M.B.; Sabo, E.; Lis, R.T.; Rosinha, E.; Liu, Q.; Hsieh, C.C.; Bhat, G.; Frackel-ton, A.R., Jr; Hafer, L.J. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin. Cancer Res., 2007, 13(19), 5798-5804.
165. Liu, G.; Xie, B.; Gong, L.; Zhou, J.; Shu, G. The expression of p66Shc protein in benign, premalignant, and malignant gastrointestinal lesions. Pathol. Oncol. Res., 2014, 20(3), 733-739.
166. Benbrook, D.M.; Nammalwar, B.; Long, A.; Matsumoto, H.; Singh, A.; Bunce, R.A.; Berlin, K.D. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Invest. New Drugs, 2014, 32(3), 412-423.
167. Orsini, F.; Migliaccio, E.; Moroni, M.; Contursi, C.; Raker, V.A.; Piccini, D.; Martin-Padura, I.; Pelliccia, G.; Trinei, M.; Bono, M.; Puri, C.; Tacchetti, C.; Ferrini, M.; Man-nucci, R.; Nicoletti, I.; Lanfrancone, L.; Giorgio, M.; Pelicci, P.G. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J. Biol. Chem., 2004, 279(24), 25689-25695.
168. Michelotti, E.F.; Michelotti, G.A.; Aronsohn, A.I.; Levens, D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol. Cell. Biol., 1996, 16(5), 2350-2360.
169. Gao, R.; Yu, Y.; Inoue, A.; Widodo, N.; Kaul, S.C.; Wadhwa, R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J. Biol. Chem., 2013, 288(21), 15046-15056.
170. Na, Y.; Kaul, S.C.; Ryu, J.; Lee, J.S.; Ahn, H.M.; Kaul, Z.; Kalra, R.S.; Li, L.; Widodo, N.; Yun, C.O.; Wadhwa, R. Stress chaperone mortalin contributes to epithelial-mesenchymal transition and cancer metastasis. Cancer Res., 2016, canres.2704.2015.
171. Fishelson, Z.; Donin, N.; Zell, S.; Schultz, S.; Kirschfink, M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol., 2003, 40(2-4), 109-123.
172. Loberg, R.D.; Day, L.L.; Dunn, R.; Kalikin, L.M.; Pienta, K.J. Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia, 2006, 8(1), 69-78.
173. Zell, S.; Geis, N.; Rutz, R.; Schultz, S.; Giese, T.; Kirschfink, M. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin. Exp. Immunol., 2007, 150(3), 576-584.
174. Pilzer, D.; Fishelson, Z. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int. Immunol., 2005, 17(9), 1239-1248.
175. Pilzer, D.; Saar, M.; Koya, K.; Fishelson, Z. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int. J. Cancer, 2010, 126(6), 1428-1435.
176. Grover, A.; Priyandoko, D.; Gao, R.; Shandilya, A.; Widodo, N.; Bisaria, V.S.; Kaul, S.C.; Wadhwa, R.; Sundar, D. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence. Int. J. Biochem. Cell Biol., 2012, 44(3), 496-504.
177. Wadhwa, R.; Sugihara, T.; Yoshida, A.; Nomura, H.; Reddel, R.R.; Simpson, R.; Maruta, H.; Kaul, S.C. Selective toxicity of MKT-077 to cancer cells is mediated by its bind- ing to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res., 2000, 60(24), 6818-6821.
178. Utomo, D.H.; Widodo, N.; Rifa’i, M. Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening. Bioinformation, 2012, 8(9), 426-429.
179. Deocaris, C.C.; Widodo, N.; Shrestha, B.G.; Kaur, K.; Ohtaka, M.; Yamasaki, K.; Kaul, S.C.; Wadhwa, R. Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett., 2007, 252(2), 259-269.
180. Kaul, S.C.; Aida, S.; Yaguchi, T.; Kaur, K.; Wadhwa, R. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J. Biol. Chem., 2005, 280(47), 39373-39379.
181. Koya, K.; Li, Y.; Wang, H.; Ukai, T.; Tatsuta, N.; Kawa-kami, M.; Shishido,; Chen, L.B. MKT-077, a novel rhoda-cyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res., 1996, 56(3), 538-543.
182. Ong, S.E.; Schenone, M.; Margolin, A.A.; Li, X.; Do, K.; Doud, M.K.; Mani, D.R.; Kuai, L.; Wang, X.; Wood, J.L.; Tolliday, N.J.; Koehler, A.N.; Marcaurelle, L.A.; Golub, T.R.; Gould, R.J.; Schreiber, S.L.; Carr, S.A. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA, 2009, 106(12), 4617-4622.
183. Thangudu, R.R.; Bryant, S.H.; Panchenko, A.R.; Madej, T. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. J. Mol. Biol., 2012, 415(2), 443-453.
184. Guo, W.; Wisniewski, J.A.; Ji, H. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg. Med. Chem. Lett., 2014, 24(11), 2546-2554.
185. Baker, N.M.; Der, C.J. Cancer: Drug for an ‘undruggable’ protein. Nature, 2013, 497(7451), 577-578.
186. Fuller, J.C.; Burgoyne, N.J.; Jackson, R.M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today, 2009, 14(3-4), 155-161.
187. Moos, P.J.; Edes, K.; Fitzpatrick, F.A. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc. Natl. Acad. Sci. USA, 2000, 97(16), 9215-9220.
188. Shaw, P.; Bovey, R.; Tardy, S.; Sahli, R.; Sordat, B.; Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 1992, 89(10), 4495-4499.
189. Samowitz, W.S.; Curtin, K.; Ma, K.N.; Edwards, S.; Schaffer, D.; Leppert, M.F.; Slattery, M.L. Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer, 2002, 99(4), 597-602.
190. Noske, A.; Lipka, S.; Budczies, J.; Müller, K.; Loddenkem-per, C.; Buhr, H.J.; Kruschewski, M. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer. Oncol. Rep., 2009, 22(1), 3-9.
191. Ambrosini, G.; Seelman, S.L.; Qin, L.X.; Schwartz, G.K. The cyclin-dependent kinase inhibitor flavopiridol potenti-ates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res., 2008, 68(7), 2312-2320.
192. Abdullah, A.; Sane, S.; Freeling, J.L.; Wang, H.; Zhang, D.; Rezvani, K. Nucleocytoplasmic Translocation of UBXN2A Is Required for Apoptosis during DNA Damage Stresses in Colon Cancer Cells. J. Cancer, 2015, 6(11), 1066-1078.
193. Sane, S.; Abdullah, A.; Nelson, M.E.; Wang, H.; Chauhan, S.C.; Newton, S.S.; Rezvani, K. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy. Cell Stress Chaperones, 2015.
194. Buchberger, A. From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol., 2002, 12(5), 216-221.
195. Schuberth, C.; Buchberger, A. UBX domain proteins: major regulators of the AAA ATPase Cdc48/p97. Cell. Mol. Life Sci., 2008, 65(15), 2360-2371.
196. Alexandru, G.; Graumann, J.; Smith, G.T.; Kolawa, N.J.; Fang, R.; Deshaies, R.J. UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover. Cell, 2008, 134(5), 804-816.
197. Lee, J.J.; Park, J.K.; Jeong, J.; Jeon, H.; Yoon, J.B.; Kim, E.E.; Lee, K.J. Complex of Fas-associated factor 1 (FAF1) with valosin-containing protein (VCP)-Npl4-Ufd1 and polyubiquitinated proteins promotes endoplasmic reticu-lum-associated degradation (ERAD). J. Biol. Chem., 2013, 288(10), 6998-7011.
198. Neuber, O.; Jarosch, E.; Volkwein, C.; Walter, J.; Sommer, T. Ubx2 links the Cdc48 complex to ER-associated protein degradation. Nat. Cell Biol., 2005, 7(10), 993-998.
199. Lee, J.J.; Kim, Y.M.; Jeong, J.; Bae, D.S.; Lee, K.J. Ubiq-uitin-associated (UBA) domain in human Fas associated factor 1 inhibits tumor formation by promoting Hsp70 degradation. PLoS One, 2012, 7(8), e40361.
200. Shibata, Y.; Oyama, M.; Kozuka-Hata, H.; Han, X.; Tanaka, Y.; Gohda, J.; Inoue, J. p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. Nat. Commun., 2012, 3, 1061.
201. Wu-Baer, F.; Ludwig, T.; Baer, R. The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function. Mol. Cell. Biol., 2010, 30(11), 2787-2798.
202. Kaul, Z.; Yaguchi, T.; Kaul, S.C.; Hirano, T.; Wadhwa, R.; Taira, K. Mortalin imaging in normal and cancer cells with quantum dot immuno-conjugates. Cell Res., 2003, 13(6), 503-507.
203. Renu Wadhwa, K.T. Can mortalin be a candidate target for cancer therapy? Cancer Ther., 2003, 1, 173-17.
204. Gao, R.; Kaul, Z.; Yaguchi, T.; Wadhwa, R. Mortalin Staining Pattern as a Reporter for Cell Based Anti-Cancer Drug Screening. In: Mortalin Biology: Life, Stress and Death; Wadhwa, R., Ed.; Springer Netherlands: Kaul, S. C., 2012; pp. 307-322.
205. Gao, R.; Singh, R.; Kaul, Z.; Kaul, S.C.; Wadhwa, R. Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells. J. Gerontol. A Biol. Sci. Med. Sci., 2015, 70(6), 701-713.
206. Mizukoshi, E.; Suzuki, M.; Loupatov, A.; Uruno, T.; Haya-shi, H.; Misono, T.; Kaul, S.C.; Wadhwa, R.; Imamura, T. Fibroblast growth factor-1 interacts with the glucose-regulated protein GRP75/mortalin. Biochem. J., 1999, 343(Pt 2), 461-466.
207. Wadhwa, R.; Yaguchi, T.; Hasan, M.K.; Taira, K.; Kaul, S.C. Mortalin-MPD (mevalonate pyrophosphate decarboxy-lase) interactions and their role in control of cellular proliferation. Biochem. Biophys. Res. Commun., 2003, 302(4), 735-742.
208. Takano, S.; Wadhwa, R.; Mitsui, Y.; Kaul, S.C. Identification and characterization of molecular interactions between glucose-regulated proteins (GRPs) mortalin/GRP75/ pep-tide-binding protein 74 (PBP74) and GRP94. Biochem. J., 2001, 357(Pt 2), 393-398.